科兴生物巴西新冠疫苗3期临床研究暂停 引述合作夥伴称与疫苗无关
就新冠灭活疫苗巴西III期临床研究暂停一事,科兴生物(SVA.US)公布,已经注意到媒体相关报道,并经与巴西合作夥伴布坦坦研究所沟通,该所负责人认为这一事件与疫苗无关。
科兴将就此事与巴西方面继续保持沟通。巴西的临床研究将继续严格按照GCP要求开展相关工作。对疫苗的安全性有信心。
巴西的卫生监管机构Anvisa指,已暂停中国科兴新冠病毒疫苗的临床试验,因在10月29日发生「严重不良反应」,但没有立即提供进一步细节。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.